原发灶不明癌与TNM分期:患者管理的新范式
本文讨论原发灶不明癌(CUP)长期以来缺乏解剖原发灶因而无适用分期系统的问题,指出近年AJCC TNM分期手册已对少数高度怀疑原发灶的CUP亚型(乳腺、口咽、鼻咽、黑色素瘤)允许标记为T0。作者主张借助免疫组化与分子检测结合临床特征,可将许多CUP患者诊断为推测的隐匿原发灶并归为特定癌种的T0,从而进行TNM分期、精准部位特异性治疗(SST)与预后判断。
要点
- AJCC TNM手册已对少数CUP亚型允许标记为T0(无原发肿瘤证据)。
- 免疫组化与分子检测结合临床特征可较有把握地推断隐匿原发灶。
- 推断原发灶后可进行TNM分期与精准部位特异性治疗(SST)。
核心结论
- 将部分CUP患者按推测原发灶归为特定癌种的T0并进行TNM分期,可实现精准部位特异性治疗、预后判断与疗效评估。
- 作者预期最终大多数导致CUP综合征的癌症将被识别,使CUP成为无关的临床实体。
研究设计与样本
- 本文为综述类文章,讨论CUP与TNM分期的关系及诊断范式转变。
- 文中提及现有临床 trial 数据,但未报告具体样本量或研究设计细节。
主要发现
- AJCC TNM分期手册已简要涉及少数罕见CUP亚型(乳腺、口咽、鼻咽、黑色素瘤),可标记为原发类别T0(无原发肿瘤证据)。
- 诊断病理学,尤其是免疫组化染色与分子检测,结合临床特征,现能在许多其他患者中以合理确定性诊断推测的隐匿原发灶。
- 许多CUP亚型现已满足上述标准,临床 trial 数据显示其SST结局似乎优于经验性化疗,且与有明确原发灶的对应患者相似。
- 作者指出仍需额外的前瞻性比较研究。
临床怎么用
- 对CUP患者应结合临床特征解读免疫组化与分子检测结果,尝试推断隐匿原发灶。
- 一旦肿瘤类型被揭示并分期,应进行额外分子特征分析与部位特异性治疗(SST)。
- 推断原发灶并TNM分期后可用于预后判断与疗效评估。
局限性
- SST优于经验性化疗的证据来自临床 trial 数据,仍需额外前瞻性比较研究。
- CUP亚型满足T0分类标准的范围有限,并非所有CUP患者均适用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer of unknown primary site (CUP) is a syndrome of many different metastatic cancers arising from clinically occult primary tumors. There has been no established staging system applicable since it has not been possible to identify an anatomical primary tumor. In recent years, the globally accepted American Joint Committee on Cancer TNM (tumor-node-metastasis) staging manuals briefly addressed a few rare CUP subsets with highly suspected primary tumors (breast, oropharynx, nasopharynx, melanoma) that could be designated as primary category T0 (no evidence of primary tumor). Similar logic may now be applied to many other patients and TNM staging is an evolving narrative. Diagnostic pathology, particularly immunohistochemical staining and molecular testing, interpreted in the context of clinical features are now capable of diagnosing presumptive occult primaries with reasonable certainty in many other patients creating an avenue for a T0 category as a specific cancer type. This new diagnostic paradigm of lifting the veil of the unknown for some patients and separating them from the historical nondescript CUP diagnosis allows for TNM staging, precision site-specific therapy (SST), prognostication, evaluating treatment results and continuing investigation. Once the tumor type is unmasked and staged, additional molecular characterization and SST are indicated. Many CUP subsets now meet these criteria and considerable clinical trial data have revealed that their outcomes from SST appear superior to empiric chemotherapy and similar to their counterparts with overt primary tumors, although additional prospective comparative studies are warranted. Eventually most of the cancers responsible for the enigmatic CUP syndrome will be identified, making CUP an irrelevant clinical entity.
引用
- Anthony Greco F. Cancer of unknown primary site and TNM staging: a new paradigm for patient management. Ann Oncol. 2025. PMID: 40701441. doi:10.1016/j.annonc.2025.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。